Lipella Pharmaceuticals Inc.

NasdaqCM:LIPO Stock Report

Market Cap: US$3.2m

Lipella Pharmaceuticals Management

Management criteria checks 2/4

Lipella Pharmaceuticals' CEO is Jon Kaufman, appointed in Jan 2005, has a tenure of 19.92 years. total yearly compensation is $323.38K, comprised of 63.1% salary and 36.9% bonuses, including company stock and options. directly owns 9.29% of the company’s shares, worth $293.25K. The average tenure of the management team and the board of directors is 17.3 years and 2.8 years respectively.

Key information

Jon Kaufman

Chief executive officer

US$323.4k

Total compensation

CEO salary percentage63.1%
CEO tenure19.9yrs
CEO ownership9.3%
Management average tenure17.3yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jon Kaufman's remuneration changed compared to Lipella Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$323kUS$204k

-US$5m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$3m

Dec 31 2022US$183kUS$183k

-US$3m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

-US$2m

Dec 31 2021US$914kUS$183k

-US$2m

Dec 31 2020US$183kUS$183k

-US$62k

Compensation vs Market: Jon's total compensation ($USD323.38K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.

CEO

Jon Kaufman (58 yo)

19.9yrs

Tenure

US$323,383

Compensation

Dr. Jonathan Kaufman, also known as Jon, PhD, MBA, co-founded Lipella Pharmaceuticals Inc. in 2005 and serves as its President, Chief Executive Officer, Secretary and Treasurer and Chairman of the Board of...

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Kaufman
Co-Founder19.9yrsUS$323.38k9.29%
$ 293.2k
Michael Chancellor
Co-Founder19.9yrsUS$315.08k9.07%
$ 286.3k
Douglas Johnston
Chief Financial Officer2.1yrsUS$260.00k0%
$ 0
Michele Gruber
Director of Operations14.8yrsno data0%
$ 0
Katie Johnston
Controllerno datano datano data

17.3yrs

Average Tenure

58yo

Average Age

Experienced Management: LIPO's management team is seasoned and experienced (17.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Kaufman
Co-Founder19.9yrsUS$323.38k9.29%
$ 293.2k
Michael Chancellor
Co-Founder16.9yrsUS$315.08k9.07%
$ 286.3k
William de Groat
Member of Advisory Boardno datano datano data
Roger Dmochowski
Member of Advisory Boardno datano datano data
Leaf Huang
Member of Advisory Boardno datano data5.74%
$ 181.3k
Ryan Pruchnic
Independent Director3.3yrsUS$62.50k0%
$ 0
Michael Brennan
Member of Scientific Advisory Board1.8yrsno datano data
Byong Kim
Independent Director2.8yrsUS$63.30k0%
$ 0
Naoki Yoshimura
Independent Director & Member of Advisory Board3.3yrsUS$62.50k0%
$ 0
Alessandro Villa
Chair of the Scientific Advisory Board1.8yrsno datano data
Kamal Al-Eryani
Member of Scientific Advisory Board1.8yrsno datano data
Vidya Sankar
Member of Scientific Advisory Board1.8yrsno datano data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Board: LIPO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lipella Pharmaceuticals Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group